根治性前列腺切除及扩大盆腔淋巴结清扫术前接受分期前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与传统影像检查患者的早期肿瘤学结局比较
本研究比较了机器人辅助根治性前列腺切除(RARP)及扩大盆腔淋巴结清扫(ePLND)术前接受PSMA-PET/CT分期(PSMA队列,2016-2021年)与未接受PSMA-PET/CT分期(历史队列,2013-2016年)患者的肿瘤学结局,经倾向性评分匹配后各纳入440例。PSMA队列生化复发126/440例(29%),历史队列205/440例(47%),多因素Cox回归显示术前PSMA-PET/CT分期对生化复发无进展生存有独立影响(HR 0.70,95%CI 0.55-0.89,p=0.0030)。
要点
- PSMA-PET/CT分期组生化复发126/440例(29%),历史队列205/440例(47%),log-rank检验p=0.032。
- 多因素Cox回归显示术前PSMA-PET/CT分期对生化复发无进展生存有独立影响(HR 0.70,95%CI 0.55-0.89,p=0.0030)。
- 作者认为PSMA-PET/CT分期改变了RARP及ePLND的患者选择,并与仍接受手术患者的早期肿瘤学结局改善相关。
核心结论
- 接受PSMA-PET/CT分期的患者在RARP及ePLND后生化进展无生存期长于未接受PSMA-PET/CT分期者。
- 作者认为PSMA-PET/CT分期改变了RARP及ePLND的患者选择,并与仍接受手术患者的早期肿瘤学结局改善相关。
研究设计与样本
- 将RARP及ePLND术前接受PSMA-PET/CT分期的患者(PSMA队列,2016-2021年)与未接受PSMA-PET/CT分期的患者(历史队列,2013-2016年)进行比较。
- 采用术前变量进行倾向性评分匹配以限制混杂,匹配后纳入880例患者(每队列440例)。
- 主要结局指标为生化复发无生存(BFS),生化复发定义为术后前列腺特异性抗原≥0.2 ng/ml或开始额外治疗。
主要发现
- 匹配后880例患者中,整个队列中位随访35个月(四分位距21-60)。
- PSMA队列126/440例(29%)发生生化复发,历史队列205/440例(47%)发生生化复发(log-rank检验p=0.032)。
- 多因素Cox回归分析显示术前PSMA-PET/CT分期对BFS有独立影响(HR 0.70,95%CI 0.55-0.89,p=0.0030)。
关键数值与推荐
- 生化复发定义为术后前列腺特异性抗原≥0.2 ng/ml或开始额外治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is increasingly used for primary staging in prostate cancer. Owing to accurate detection of small metastases on PSMA-PET/CT, patient selection for robot-assisted radical prostatectomy (RARP) has likely changed. This study analyzes oncological outcomes in patients undergoing RARP and extended pelvic lymph node dissection (ePLND) after PSMA-PET/CT staging, compared with those without PSMA-PET/CT. METHODS: Patients who underwent staging with PSMA-PET/CT before RARP and ePLND ("PSMA cohort"; 2016-2021) were compared with patients staged without PSMA-PET/CT ("historical cohort"; 2013-2016). Propensity score matching using preoperative variables was performed to limit confounding. As primary outcome measure of biochemical recurrence (BCR)-free survival (BFS) was analyzed, with BCR defined as a prostate specific antigen value of ≥0.2 ng/ml or start of additional therapy after surgery. KEY FINDINGS AND LIMITATIONS: After matching, 880 patients were included (440 in each cohort). The median follow-up was 35 mo (interquartile range 21-60) for the entire cohort. In the PSMA cohort, 126/440 patients (29%) experienced BCR versus 205/440 (47%) in the historical cohort (log-rank test p = 0.032). A multivariable Cox regression analysis showed an independent effect of preoperative PSMA-PET/CT staging on BFS (hazard ratio 0.70, 95% confidence interval 0.55-0.89, p = 0.0030). CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients who underwent staging with PSMA-PET/CT had longer biochemical progression-free survival after RARP and ePLND than those without PSMA-PET/CT. This suggests that PSMA-PET/CT staging alters patient selection for RARP and ePLND, and is associated with improved early oncological outcomes for patients who still undergo surgery. PATIENT SUMMARY: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) at the diagnosis of prostate cancer leads to better visualization of metastases and therefore better selection of prostate cancer patients for surgery. Patients who underwent a PSMA-PET/CT scan at the time of diagnosis showed improved oncological outcomes, including longer progression-free survival and less prostate-specific antigen persistence after surgery.
引用
- Ettema RH, Mellema JJ, Meijer D, et al. Early Oncological Outcomes in Patients who Underwent Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging Before Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Eur Urol Oncol. 2024. PMID: 39694797. doi:10.1016/j.euo.2024.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。